{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:25:02Z","timestamp":1773296702631,"version":"3.50.1"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T00:00:00Z","timestamp":1539907200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2018.01200","type":"journal-article","created":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T14:15:03Z","timestamp":1539958503000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["PBF509, an Adenosine A2A Receptor Antagonist With Efficacy in Rodent Models of Movement Disorders"],"prefix":"10.3389","volume":"9","author":[{"given":"Fabiana","family":"N\u00fa\u00f1ez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaume","family":"Taura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Camacho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"L\u00f3pez-Cano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00edctor","family":"Fern\u00e1ndez-Due\u00f1as","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi","family":"Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Ciruela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2018,10,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1021\/cn5001606","article-title":"JNJ-40255293, a novel adenosine A2A\/A1 antagonist with efficacy in preclinical models of Parkinson\u2019s disease.","volume":"5","author":"Atack","year":"2014","journal-title":"ACS Chem. Neurosci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1093\/brain\/awh128","article-title":"Increased adenosine A2A receptors in the brain of Parkinson\u2019s disease patients with dyskinesias.","volume":"127","author":"Calon","year":"2004","journal-title":"Brain"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1523\/JNEUROSCI.3574-05.2006","article-title":"Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers.","volume":"26","author":"Ciruela","year":"2006","journal-title":"J. Neurosci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/ilar.38.1.41","article-title":"Special report: the 1996 guide for the care and use of laboratory animals.","volume":"38","author":"Clark","year":"1997","journal-title":"ILAR J."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1111\/j.1476-5381.2011.01426.x","article-title":"Animal models of Parkinson\u2019s disease: a source of novel treatments and clues to the cause of the disease.","volume":"164","author":"Duty","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"841","DOI":"10.2165\/00023210-200822100-00005","article-title":"Cost effectiveness of pharmacotherapies in early Parkinson\u2019s disease.","volume":"22","author":"Eggert","year":"2008","journal-title":"CNS Drugs"},{"key":"B7","first-page":"S2","article-title":"The spectrum of levodopa-induced dyskinesias.","volume":"47","author":"Fahn","year":"2000","journal-title":"Ann. Neurol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1242\/dmm.018143","article-title":"Untangling dopamine-adenosine receptor-receptor assembly in experimental parkinsonism in rats.","volume":"8","author":"Fern\u00e1ndez-Due\u00f1as","year":"2015","journal-title":"Dis. Models Mech."},{"key":"B9","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.parkreldis.2004.02.014","article-title":"Adenosine A2A-dopamine D2 receptor-receptor heteromers. Targets for neuro-psychiatric disorders.","volume":"10","author":"Ferre","year":"2004","journal-title":"Parkinsonism Relat. Disord."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.2174\/138161208784480108","article-title":"An update on adenosine A2A-dopamine D2 receptor interactions. Implications for the function of G protein-coupled receptors.","volume":"14","author":"Ferre","year":"2008","journal-title":"Curr. Pharm. Design"},{"key":"B11","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/S1474-4422(08)70214-X","article-title":"Non-dopaminergic treatments in development for Parkinson\u2019s disease.","volume":"7","author":"Fox","year":"2008","journal-title":"Lancet Neurol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.bbr.2015.04.001","article-title":"Adenosine A2A receptor-mediated control of pilocarpine-induced tremulous jaw movements is Parkinson\u2019s disease-associated GPR37 receptor-dependent.","volume":"288","author":"Gand\u00eda","year":"2015","journal-title":"Behav. Brain Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1126\/science.2147780","article-title":"D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons.","volume":"250","author":"Gerfen","year":"1990","journal-title":"Science"},{"key":"B14","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1021\/jm800961g","article-title":"Antagonists of the human A(2A) adenosine receptor. 4. Design, synthesis, and preclinical evaluation of 7-aryltriazolo[4,5-d]pyrimidines.","volume":"52","author":"Gillespie","year":"2009","journal-title":"J. Med. Chem."},{"key":"B15","doi-asserted-by":"publisher","first-page":"471","DOI":"10.2165\/00002512-200522060-00002","article-title":"Adenosine A2A receptor antagonists for Parkinson\u2019s disease: rationale, therapeutic potential and clinical experience.","volume":"22","author":"Hauser","year":"2005","journal-title":"Drugs Aging"},{"key":"B16","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.bios.2015.06.031","article-title":"Whole-cell biosensor for label-free detection of GPCR-mediated drug responses in personal cell lines.","volume":"74","author":"Hillger","year":"2015","journal-title":"Biosens. Bioelectron."},{"key":"B17","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1124\/jpet.108.149617","article-title":"Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movemen.","volume":"330","author":"Hodgson","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1124\/pr.111.005678","article-title":"The pharmacology of L-DOPA-induced dyskinesia in Parkinson\u2019s disease.","volume":"65","author":"Huot","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"B19","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1517\/13543784.14.6.729","article-title":"Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson\u2019s disease.","volume":"14","author":"Jenner","year":"2005","journal-title":"Expert Opin. Investig. Drugs"},{"key":"B20","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.parkreldis.2008.12.006","article-title":"Adenosine, adenosine A 2A antagonists, and Parkinson\u2019s disease.","volume":"15","author":"Jenner","year":"2009","journal-title":"Parkinsonism Relat. Disord."},{"key":"B21","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/0014-2999(94)90551-7","article-title":"KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity.","volume":"256","author":"Kanda","year":"1994","journal-title":"Eur. J. Pharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/WNF.0000000000000073","article-title":"A long-term study of istradefylline safety and efficacy in patients with Parkinson disease.","volume":"38","author":"Kondo","year":"2015","journal-title":"Clin. Neuropharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/0165-6147(93)90080-4","article-title":"Further concerns over Cheng-Prusoff analysis.","volume":"14","author":"Leff","year":"1993","journal-title":"Trends Pharmacol. Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/ana.21315","article-title":"Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces \u201coff\u201d time in Parkinson\u2019s disease: a double-blind, randomized, multicenter clinical trial (6002-US-005).","volume":"63","author":"LeWitt","year":"2008","journal-title":"Ann. Neurol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0014-2999(97)00066-6","article-title":"The behavioural effects of pramipexole, a novel dopamine receptor agonist.","volume":"324","author":"Maj","year":"1997","journal-title":"Eur. J. Pharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.neo.2017.02.004","article-title":"a novel antagonist of the immune checkpoint protein adenosine A2a receptor restores tumor-infiltrating lymphocyte activity in the context of the tumor microenvironment.","volume":"19","author":"Mediavilla-Varela","year":"2017","journal-title":"Neoplasia"},{"key":"B27","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/nrd3430","article-title":"Priorities in Parkinson\u2019s disease research.","volume":"10","author":"Meissner","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1002\/mds.23107","article-title":"Clinical efficacy of istradefylline (KW-6002) in Parkinson\u2019s disease: a randomized, controlled study.","volume":"25","author":"Mizuno","year":"2010","journal-title":"Mov. Disord."},{"key":"B29","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1517\/14740338.2015.1014798","article-title":"The safety of istradefylline for the treatment of Parkinson\u2019s disease.","volume":"14","author":"M\u00fcller","year":"2015","journal-title":"Expert Opin. Drug Saf."},{"key":"B30","first-page":"547","volume":"170","author":"Paxinos","year":"2007","journal-title":"The Rat Brain in Stereotaxic Coordinates"},{"key":"B31","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s40263-014-0161-7","article-title":"Adenosine A2A receptor antagonists in Parkinson\u2019s disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued.","volume":"28","author":"Pinna","year":"2014","journal-title":"CNS Drugs"},{"key":"B32","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1212\/WNL.0b013e31819908ce","article-title":"Treatments for Parkinson disease\u2013past achievements and current clinical needs.","volume":"72","author":"Poewe","year":"2009","journal-title":"Neurology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/S1353-8020(09)70831-4","article-title":"The clinical progression of Parkinson\u2019s disease.","volume":"15","author":"Poewe","year":"2009","journal-title":"Parkinsonism Relat. Disord."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1212\/WNL.0b013e31821ccce4","article-title":"Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease.","volume":"76","author":"Ramlackhansingh","year":"2011","journal-title":"Neurology"},{"key":"B35","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ejphar.2006.07.017","article-title":"The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets.","volume":"546","author":"Rose","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.euroneuro.2012.08.004","article-title":"Conditional neural knockout of the adenosine A(2A) receptor and pharmacological A(2A) antagonism reduce pilocarpine-induced tremulous jaw movements: studies with a mouse model of Parkinsonian tremor.","volume":"23","author":"Salamone","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/S0301-0082(98)00053-7","article-title":"Tremulous jaw movements in rats: a model of parkinsonian tremor.","volume":"56","author":"Salamone","year":"1998","journal-title":"Prog. Neurobiol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/nrd2087","article-title":"Novel pharmacological targets for the treatment of Parkinson\u2019s disease.","volume":"5","author":"Schapira","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"B39","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.pneurobio.2007.05.001","article-title":"Adenosine A2A receptors and basal ganglia physiology.","volume":"83","author":"Schiffmann","year":"2007","journal-title":"Prog. Neurobiol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S0301-0082(96)00040-8","article-title":"The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments.","volume":"50","author":"Schwarting","year":"1996","journal-title":"Prog. Neurobiol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.tins.2006.09.004","article-title":"Targeting adenosine A2A receptors in Parkinson\u2019s disease.","volume":"29","author":"Schwarzschild","year":"2006","journal-title":"Trends Neurosci."},{"key":"B42","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s002130051146","article-title":"Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP.","volume":"147","author":"Shiozaki","year":"1999","journal-title":"Psychopharmacology"},{"key":"B43","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.expneurol.2004.05.027","article-title":"Blockade of adenosine A2A receptors antagonizes parkinsonian tremor in the rat tacrine model by an action on specific striatal regions.","volume":"189","author":"Simola","year":"2004","journal-title":"Exp. Neurol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1089\/adt.2004.2.363","article-title":"Application of real-time cell electronic sensing (RT-CES) technology to cell-based assays.","volume":"2","author":"Solly","year":"2004","journal-title":"Assay Drug Dev. Technol."},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0029420","article-title":"Impedance responses reveal \u03b22-adrenergic receptor signaling pluridimensionality and allow classification of ligands with distinct signaling profiles.","volume":"7","author":"Stallaert","year":"2012","journal-title":"PLoS One"},{"key":"B46","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.ejphar.2015.03.070","article-title":"Animal models of Parkinson\u2019s disease: effects of two adenosine A2A receptor antagonists ST4206 and ST3932, metabolites of 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine (ST1535).","volume":"761","author":"Stasi","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/0471143030.cb1717s67","article-title":"Visualizing G protein-coupled receptor-receptor interactions in brain using proximity ligation in situ assay.","volume":"67","author":"Taura","year":"2015","journal-title":"Curr. Protoc. Cell Biol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/978-1-4939-3064-7_28","article-title":"Determination of GPCR-mediated cAMP accumulation in rat striatal synaptosomes.","volume":"110","author":"Taura","year":"2016","journal-title":"Neuromethods"},{"key":"B49","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.1021\/jm0009843","article-title":"Design, radiosynthesis, and biodistribution of a new potent and selective ligand for in vivo imaging of the adenosine A(2A) receptor system using positron emission tomography.","volume":"43","author":"Todde","year":"2000","journal-title":"J. Med. Chem."},{"key":"B50","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ejphar.2007.03.021","article-title":"Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats.","volume":"566","author":"Tronci","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"659","DOI":"10.2174\/187152711797247803","article-title":"An update on adenosine A2A receptors as drug target in Parkinson\u2019s disease.","volume":"10","author":"Vallano","year":"2011","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"B52","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1006\/nbdi.2002.0499","article-title":"L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of Parkinson\u2019s disease: relation to motor and cellular parameters of nigrostriatal function.","volume":"10","author":"Winkler","year":"2002","journal-title":"Neurobiol. Dis."},{"key":"B53","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.bios.2015.10.027","article-title":"A review of impedance measurements of whole cells.","volume":"77","author":"Xu","year":"2016","journal-title":"Biosens. Bioelectron."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1046\/j.1460-9568.2000.00988.x","article-title":"Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPA.","volume":"12","author":"Zeng","year":"2000","journal-title":"Eur. J. Neurosci."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2018.01200\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T14:15:05Z","timestamp":1539958505000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2018.01200\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,19]]},"references-count":54,"alternative-id":["10.3389\/fphar.2018.01200"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2018.01200","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,19]]},"article-number":"1200"}}